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A mast cell-ILC2-Th9 pathway promotes lung
inﬂammation in cystic ﬁbrosis
Silvia Moretti1, Giorgia Renga1, Vasilis Oikonomou1, Claudia Galosi1, Marilena Pariano1, Rossana G. Iannitti1,
Monica Borghi1, Matteo Puccetti1, Marco De Zuani2, Carlo E. Pucillo2, Giuseppe Paolicelli1, Teresa Zelante1,
Jean-Christophe Renauld3, Oxana Bereshchenko4, Paolo Sportoletti5, Vincenzina Lucidi6, Maria Chiara Russo7,
Carla Colombo7, Ersilia Fiscarelli8, Cornelia Lass-Flo¨rl9, Fabio Majo6, Gabriella Ricciotti8, Helmut Ellemunter10,
Luigi Ratclif11, Vincenzo Nicola Talesa1, Valerio Napolioni1 & Luigina Romani1
T helper 9 (Th9) cells contribute to lung inﬂammation and allergy as sources of interleukin-9
(IL-9). However, the mechanisms by which IL-9/Th9 mediate immunopathology in the lung
are unknown. Here we report an IL-9-driven positive feedback loop that reinforces allergic
inﬂammation. We show that IL-9 increases IL-2 production by mast cells, which leads to
expansion of CD25þ type 2 innate lymphoid cells (ILC2) and subsequent activation of Th9
cells. Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts the pathogenic effect of
the described IL-9-mast cell-IL-2 signalling axis. Overproduction of IL-9 is observed in
expectorates from cystic ﬁbrosis (CF) patients, and a sex-speciﬁc variant of IL-9 is predictive
of allergic reactions in female patients. Our results suggest that blocking IL-9 may be a
therapeutic strategy to ameliorate inﬂammation associated with microbial colonization in the
lung, and offers a plausible explanation for gender differences in clinical outcomes of patients
with CF.
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I
nnate lymphoid cells (ILCs) perform a variety of immune
functions at barrier surfaces1. Three types of ILCs have been
reported, which differ on the basis of the cytokines produced.
ILC1 encompass natural killer cells and interferons (IFN)-g-
releasing cells; ILC2 release IL-5, IL-9 and IL-13, and ILC3 release
IL-17A and IL-22. ILC2 preferentially localize to the interface
between the host and the environment (lung, intestine and skin)
and perform a variety of biological functions in mice2 and
humans3. In the lung, ILC2 and their cytokines play pro-
inﬂammatory roles in allergic inﬂammation2,4,5, but also
protective roles in airway epithelial cell repair and control of
tissue inﬂammation linked to pathogens6,7. Thus, ILC2 may affect
the course of airways diseases, resulting in either pathological or
protective outcomes. Lung ILC2 rapidly produces IL-5 and IL-13
on exposure to IL-33 (ref. 5), an effect potentiated by IL-25 and
thymic stromal lymphopoietin (TSLP)5, and IL-9 on the exposure
to IL-2 (ref. 8). By promoting ILC2 survival8, IL-9 provides a
positive feedback loop that ampliﬁes ILC2 cytokine production
and the ensuing allergic airway inﬂammation9. However, IL-9
also dampens the pathogenic activities of Th17 cells10 and
mediates tolerance imparted by regulatory T cells (Treg) via mast
cells (MC)11. Produced by MC, in addition to ILC2 and Th9, IL-9
in turn affects the expansion12 and function13 of MC, which are
known to have positive, as well as negative, immunomodulatory
roles in vivo13–16. Thus, IL-9, like ILC2, may have different roles
in lung immune homeostasis.
In patients with cystic ﬁbrosis (CF), the primary source of
morbidity and mortality is due to a vicious cycle of airway
infection and inﬂammation eventually resulting in lung damage.
The inﬂammatory response in CF is dysregulated at several levels,
resulting in inefﬁcient microbial clearance and contributing
to lung damage17. This is supported by several studies that
have documented an altered balance of inﬂammatory/anti-
inﬂammatory cytokines in CF (ref. 17), providing evidence that
targeting speciﬁc inﬂammatory/anti-inﬂammatory pathways is a
valid therapeutic strategy in CF (ref. 18). This balance is essential
for the efﬁcient control of Aspergillus fumigatus diseases in CF
(ref. 18), where the colonization by the fungus is common
and may lead to fungal sensitization, bronchitis and allergic
broncho-pulmonary aspergillosis (ABPA)19 as well as worse
forced expiratory volume in the ﬁrst second (FEV1) (ref. 20). In
CF patients, the expression of IL-9 and IL-9R is increased and is
associated with mucus overproduction, but whether and how IL-9
contributes to immunity and pathology in response to the fungal
infection in CF is not known.
In the present study, we determine the contribution of IL-9 to
Aspergillus infection and allergy in murine and human CF, and
assess the therapeutic effectiveness of targeting IL-9-dependent
pathways and the diagnostic potential of this approach. We ﬁnd
that IL-9-driven IL-2 production by MC expands CD25þ ILC2,
which in turn activate Th9 cells, leading to an ampliﬁed allergic
inﬂammation. Overproduction of IL-9 is observed in expectorates
from CF patients and a genetic variant of IL-9 shows a
sex-speciﬁc association with IgE levels in female patients.
Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts
the pathogenic potential of the IL-9-MC-IL-2 axis, thus providing
a therapeutic angle to ameliorate the pathological consequences
of microbial colonization in CF.
Results
IL-9 production and ILC2-Th9 activation during aspergillosis.
We infected C57BL/6 or Cftr /mice intranasally with
A. fumigatus and measured IL-9 production, ILC2 and Th9 cell
activation in infection. We have already shown that Cftr /mice
are susceptible to Aspergillus infection (from 2.5±0.7 to
3.9±1.0 log colony forming unit (cfu)±s.d. per lung, C57BL/6
versus Cftr /mice, respectively) and allergy (from 9.2±0.7 to
22.4±1.3 ngml 1 total serum IgE in C57BL/6 and Cftr /
mice, respectively). A peak production of IL-9 occurred during
the ﬁrst week of the infection in C57BL/6 mice to decline
thereafter as opposed to Cftr /mice in which levels of IL-9
were sustained throughout the infection (Fig. 1a). Peak produc-
tion of IL-9 was also observed in Rag1 / , and less in
Rag1 / /Il9R / , mice early but not late in infection (Fig. 1a),
a ﬁnding suggesting that early IL-9 production is IL-9R-depen-
dent and late is T-cell-dependent. We looked therefore for the
presence of IL-9þ ILC2 and Th9 cells in infection by character-
izing IL-9-producing Lin and CD4þ T cells in the lung. ILC2
are marked by expression of the IL-33R as well as the common g
chain (gc) cytokine receptors for IL-2 and IL-7 (ref. 2). Flow
cytometry analysis revealed that CD90.2þ ILC2 expressing IL33R
or CD25 were present in the lung of naive C57BL/6 (4.5 and 3.3%
for CD25þ and ST2þ cells, respectively) and Cftr /mice (5.8
and 4.0% for CD25þ and ST2þ cells, respectively; Fig. 1b,c). In
C57BL/6 mice, and similarly in Rag1 / mice (Supplementary
Fig. 1a), ST2þ ILC2 cells decreased early in infection to return to
baseline level 10 days later while CD25þ ILC2 stably decreased
(Fig. 1b,c). In contrast, in Cftr /mice, both types of ILC2
steadily increased throughout the infection (Fig. 1b) along with
the expression of the ILC2 transcription factors, Rora, and Gata3
(Fig. 1d) and the production of ILC2 effector cytokines, IL-5 and
IL-13 (Fig. 1e). IL-9-producing CD90.2þ ILC2 were also expan-
ded in Cftr /mice but not in C57BL/6 (Fig. 1b,c) and
Rag1 / mice (Supplementary Fig. 1a), as revealed by ﬂow
cytometry. In terms of Th9 cell activation, CD4þ IL-9þ T cells
appeared in C57BL/6 mice a week after the infection to decline
thereafter (Fig. 1h), consistent with the short retention of Th9 at
the inﬂammatory sites21. The expansion was instead sustained in
Cftr /mice (Fig. 1h) along with the expression of Il9, Pu.1
(purine-rich box 1) and Irf4 (interferon regulatory factor 4)
transcription factors (Fig. 1g). These data indicate that
IL-9þ ILC2 and Th9 cells are all increased in Cftr /mice
during A. fumigatus infection.
Given that ILC1 through IFN-g (ref. 22) and ILC3 through
IL-22 (ref. 23) may affect ILC2 expansion, the differential
expansion of ILC2 could reﬂect the ILCs dynamics in the lung.
However, NKp46þNK1.1þ ILC1 cells producing IFN-g did not
expand and ILC1-promoting cytokines IL-15 and IL-18 were not
produced in Cftr / as opposed to C57BL/6 mice
(Supplementary Fig. 2a,b). Similarly, despite expanded in
Cftr /mice, CCR6þRORgtþ ILC3 produced IL-17A more
than IL-22 (Supplementary Fig. 2c,d). Thus, while conﬁrming the
defective production of IFN-g and IL-22 in Cftr / mice18,
these ﬁndings suggest that the expansion of ILC2 in Cftr /mice
is not dependent on ILCs dynamics in the lung but rather on the
production of ILC2 promoting cytokines. This appeared to be the
case, as the levels of cytokines promoting ST2þ ILC2, IL-33 and
CD25þ ILC2, IL-2, were constantly elevated in Cftr /mice
whereas a peak production was only observed at an early time
point in C57BL/6 mice (Fig. 1f).
IL-9 contributes to inﬂammatory pathology in infection. To
assess the role of IL-9 in A. fumigatus infection and allergy, we
resorted to Il9R /mice that, given the crucial role of the IL-9R,
a member of the gc receptor family, for the survival of lung
ILC2 (ref. 8), also have a decreased ILC2 (ref. 8). Mice were
either acutely infected with Aspergillus conidia intranasally or
subjected to fungal allergy (ABPA) by repeated sensitization with
Aspergillus culture ﬁltrate extracts (5.5±0.7 ngml 1 versus
11±1.0, total serum IgE in Il9R / versus C57BL/6 mice,
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respectively). We found that the absence of IL-9R signalling
conferred resistance to both infection and allergy, as indicated by
the reduced fungal load (Fig. 2a) and decreased inﬂammatory
lung pathology in infection as well as in ABPA (Fig. 2b). The
numbers of lung CD25þ and ST2þ ILC2 were decreased in these
mice as revealed by immunoﬂuorescence staining (Fig. 2c).
Concomitantly, Th9 and, partially, Th2 cells—revealed by
Stat6 expression and STAT5 phosphorylation (Supplementary
Fig. 1b,c)—were decreased in both infection and allergy
(Fig. 2d,e), while Th17 and Treg cells were unaffected and Th1
cells increased (Supplementary Fig. 3a,b). Corroborating these
ﬁndings, IL-9 neutralization in C57BL/6 or Cftr /mice greatly
ameliorated lung pathology in response to the fungus, both in
terms of inﬂammatory cell recruitment (Fig. 2f) and ﬁbrosis as
shown by Masson’s trichrome staining (insets of Fig. 2f) and
production of TGF-b (Fig. 2g), a mediator of pulmonary
ﬁbrosis24. Together, these results indicate that the IL-9/IL-9R
signalling pathway is required for the expansion of pathogenic
ILC2 and Th9 cells in response to the fungus. However, whether
ILC2 promote Th9 cell activation via IL-9R signalling is not
known. To directly assess this, we did criss-cross experiments in
which CD4þ T cells from either C57BL/6 or Cftr /mice were
assessed for IL-9 production and Th9 transcription factor
expression on co-cultivation in a transwell permeable support
with lung Lin cells exposed to A. fumigatus and either IL-2 or
IL-33. We found that Th9 cell activation was observed upon
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Figure 1 | IL-9 production and ILC2-Th9 cells activation in Aspergillus fumigatus infection. (a) Time course of IL-9 production at various days post
infection (dpi) in mice (six per group) infected intranasally with live A. fumigatus conidia. (b) Detection of CD90.2þCD25þ , CD90.2þST2þ and
CD90.2þ IL-9þ lung type 2 ILCs by ﬂow cytometry (numbers refer to percentages of positive cells) and immunoﬂuorescence staining. (c) Absolute
number of lung ILC2; (d) ILC2–speciﬁc transcript on lineage negative lung cells; (e,f) ILC2 effector and activating cytokines; (g) Il9 and Th9-cell speciﬁc
transcripts on lung CD4þ T cells and (h) immunoﬂuorescence staining of lung CD4þ IL-9þ T cells. Photographs were taken with a high-resolution
microscope (Olympus DP71) equipped with a 40 objective; scale bar, 100mm. Mean values±s.d. cytokines were determined on lung homogenates by
ELISA, Il9 and transcripts assessed by PCR with reverse transcription. 0, uninfected mice. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, knockout
versus C57BL/6 mice (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Gata3,
GATA binding protein 3; Irf4, interferon regulatory factor 4; Pu.1, purine-rich box 1; Rora, RAR-related orphan receptor alpha.
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Figure 2 | IL-9R signaling contributes to inﬂammation and allergy. C57BL/6 and Il9R / mice (six per group) were intranasally infected with live
Aspergillus fumigatus conidia or subjected to ABPA and assessed for (a) lung fungal growth (log10 cfu, mean±s.d.); (b) lung histology (periodic acid Schiff
staining); (c) expression of CD90.2þCD25þ , CD90.2þST2þ lung ILC2 by immunoﬂuorescence; (d,e) Th-cell speciﬁc transcripts and cytokine
production. (f) Lung histology (periodic acid–Schiff and, in the inset, Masson’s trichrome staining) and (g) TGF-b production in C57BL/6 or Cftr/ mice
infected as above and treated with IL-9 neutralizing antibody for a week. Days post infection (dpi). (h) Th-cell speciﬁc transcripts and IL-9 production of
lung CD4þ T cells from naive mice co-cultured with lung lineage negative (Lin ) cells in the presence of A. fumigatus conidia, IL-2 or IL-33. Photographs
were taken with a high-resolution microscope (Olympus DP71) equipped with a  20 objective; scale bars, 200mm and a 40 objective (insets of f,
scale bars, 100 mm). Results are mean values±s.d., ELISA was done on lung homogenates and culture supernatants for cytokines and PCR with reverse
transcription on CD4þ lung cells. *Po0.05, **Po0.01, ***Po0.001, Il9R / , Cftr/ versus C57BL/6 mice; IL-9-treated versus control isotype-treated
mice; stimulated versus unstimulated (none) cells and Il9R / versus C57BL/6 or Cftr/ CD4þ Tcells. Naive, uninfected mice. Data represent pooled
results or representative images from three experiments, Two-tailed Student’s t-test (a) or Two-way ANOVA (d,e) Bonferroni post test. Gata3, GATA
binding protein 3; Irf4, interferon regulatory factor 4; Pu.1, purine-rich box 1.
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co-cultivation of CD4þ T cells with Lin cells in the presence of
IL-2 more than IL-33, an effect magniﬁed in Cftr / as
compared to C57BL/6 mice (Fig. 2h), and requiring the
presence of IL-9R on responder CD4þ T cells being
signiﬁcantly negated with Il9R / responder cells (Fig. 2h and
Supplementary Fig. 4). These results indicate that ILC2, and
particularly CD25þ ILC2, may account for the sustained IL-9
production and Th9 activation responsible for pathology in CF.
IL-9 activates mast cells to produce IL-2. The sustained
production of IL-33 and IL-2 in Cftr /mice prompted us to
investigate mechanisms behind this production. IL-33 is
constitutively expressed at epithelial barrier surfaces where it is
rapidly released from cells during tissue injury25. However,
tight regulation of IL-33 following its release to dampen
ST2-dependent inﬂammation to fungi has also been
described26. This likely occurred in C57BL/6 but not in Cftr /
mice in which the high levels of epithelial damage observed
upon the infection (Fig. 3a) likely accounted for the sustained
IL-33-dependent ST2þ ILC2 expansion. For IL-2, predictably
high in CF, given the sustained NFAT activity27, in addition to
CD4þ T cells8 and dendritic cells28, MC are known to produce it
in the lung7. We looked therefore for MC presence and activity in
the lung of C57BL/6 and Cftr /mice after the infection. MC
were much expanded in Cftr / mice, as seen by ﬂow cytometry
(Fig. 3b) and toluidine staining (Fig. 3c). MC are distinguished by
their granule content whose expression is tissue-dependent29. In
the lung, chymase-positive MC numbers positively correlated
with better lung function30, whereas chymase- and tryptase-
positive MC were expanded in areas of ﬁbrosis in CF lungs and
positively correlated with the degree of ﬁbrosis and lung
function31. Immunohistochemistry revealed that while tryptase-
positive cells could not be detected, chymase-positive MC
were present in C57BL/6 mice (insets of Fig. 3c). In contrast,
chymase-positive and tryptase-positive MC were observed in
Cftr / mice (insets of Fig. 3c).
As MC are known to produce cytokines through different
receptor mechanisms32, we evaluated cytokine production on
magnetically puriﬁed c-Kitþ MC (as characterized by
morphometry and MC speciﬁc transcripts, Fig. 3d) upon
stimulation with IgE, IL-9 or IL-33. We found that IL-2
production was induced by IL-33 and, more, by IL-9 and not
by IgE, mostly in MC from Cftr /mice (Fig. 3e). As IL-9 also
induced IL-9 production (Fig. 3e) and IL-9þMC could also be
detected in vivo (Fig. 3b), this suggests that an autocrine loop
appears to mediate the IL-9-dependent IL-2 release by MC. As a
matter of fact, IL-2 production (39±6 ng/ml versus 127±22,
IL-2 in lung homogenates at 3 dpi in Il9R / versus C57BL/6
mice, respectively) and IL-2þMC (Fig. 3f) were greatly reduced
in Il9R /mice, thus contributing to the defective expansion of
CD25þ ILC2 in these mice. Of interest, IL-9 stimulation also
induced TGF-b in MC from Cftr /mice but not IL-6 (Fig. 3e),
a ﬁnding suggesting that the autocrine IL-9 stimulation appears
to be speciﬁc for IL-2 and TGF-b (Fig. 3e). These data indicate
that MC may contribute to IL-2 production eventually leading to
CD25þ ILC2 expansion in Cftr /mice. This appears to be the
case, as IL-2þMC, more than IL-2þCD90.2 or IL-2þCD4þ
T cells, were expanded in vivo, early in infection, particularly in
Cftr /mice (Fig. 3f).
To directly prove this, we assessed susceptibility to inﬂamma-
tory allergy of MC-deﬁcient C57BL/6-KitW/W-v mice or Cftr /
mice treated with the tyrosine kinase inhibitor imatinib known to
inhibit IL-9-driven mastocytosis in the lung12. Airway
mastocytosis was reduced in MC-deﬁcient KitW/W-v mice
(Fig. 4a) along with reduced levels of IgE, IL-2, IL-9 and
TGF-b (Fig. 4b). Concomitantly, the number of CD25þ ILC2
were also decreased in the lung but promptly restored upon MC
engraftment or exogenous IL-2 administration (Fig. 4a). Thus,
MC appear to be able to control CD25þ ILC2 expansion in the
lung during the infection via IL-2. Similar results were obtained
upon treatment of Cftr / mice with imatinib. Both
inﬂammation (Fig. 4c), collagen deposition (insets of Fig. 4c),
IL-2, IL-9 and TGF-b production (Fig. 4d) and Th9 cell activation
(Fig. 4e) were attenuated. Interestingly, imatinib apparently
increased early inﬂammation in C57BL/6 mice (Supplementary
Fig. 5), a ﬁnding suggesting that c-Kitþ cells could contribute to
pathogen resistance early in infection. As a matter of fact, MC-
deﬁcient KitW/W-v mice displayed increased susceptibility to the
infection as compared with C57BL/6 mice, as indicated by the
increased fungal load (Supplementary Fig. 6a), neutrophils
recruitment (Supplementary Fig. 6b) and a degree of lung
inﬂammation (Supplementary Fig. 6c).
CFTR deﬁciency contributes to inﬂammation. The above
results suggest that a circuit involving IL-33, IL-2 and IL-9 and
different types of cells is pathogenically ampliﬁed in Cftr /
mice. The ﬁnding that IL-33, IL-2 and IL-9 are also elevated in CF
patients33,34 prompted us to evaluate the contribution of cystic
ﬁbrosis transmembrane conductance regulator (CFTR)
dysfunction on the activation of the inﬂammatory circuit.
Given that CFTR dysfunction on both epithelial and myeloid
cells impacts on lung inﬂammation35, we assessed chimeric mice
with CFTR unresponsive myeloid or epithelial cells for lung
damage and inﬂammation, production of IL-33, IL-2 and IL-9
and MC/ILC2 activation upon Aspergillus infection. We found
that epithelial cell damage and lung inﬂammation (Fig. 5a), levels
of cytokines and IgE (Fig. 5b), MC and ILC2 expansion (Fig. 5c)
were all attenuated or decreased in condition of CFTR deﬁciency
in epithelial cells but CFTR sufﬁcient myeloid cells, a ﬁnding
suggesting that myeloid, and perhaps lymphoid, deﬁciency could
contribute to the activation of the inﬂammatory circuit in CF.
This seems to be the case as the opposite ﬁndings were observed
in recipient C57BL/6 mice receiving CFTR deﬁcient myeloid cells
(Fig. 5a,c) These mice, however, showed an intermediate
inﬂammatory phenotype as compared to Cftr / mice, a
ﬁnding suggesting that, although to a different extent, CFTR
deﬁciency on epithelial and myeloid cells may predispose to lung
inﬂammation in response to microbial and non-microbial stimuli.
The IL9 rs2069885 SNP correlates with high IgE levels in CF
females. To assess whether IL-9 may contribute to allergy in CF
patients, we determined the effect of the non-synonymous IL9
p.Thr117Met (c.350C4T, rs2069885) polymorphism, known to
be associated with lung function and sensitization36,37 on total
and Aspergillus-speciﬁc IgE levels in CF patients (Supplementary
Table 1). Previous association studies demonstrated the existence
of sex dimorphism linked to this polymorphism36,37. Therefore,
we carried out association testing separately in males and
females. The distribution of the total IgE was skewed but after
natural logarithmic transformation, the distribution adequately
approximated a normal distribution. IL9 rs2069885 genotype
distribution did not deviate from Hardy–Weinberg equilibrium
(w2 test, P¼ 0.776) and it displayed a minor allele frequency of
0.129, comparable to the European population from 1000
Genome Consortium, minor allele frequency¼ 0.128 (ref. 38).
IL9 rs2069885 genotype distribution did not differ between males
and females (w2 test, P¼ 0.243), but a signiﬁcant rs2069885-sex
interaction on total IgE levels was found (general linear model,
P¼ 0.004), where female T allele carriers showed high IgE
levels (linear regression: females, b¼ 0.624, P¼ 0.043; males,
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b¼  0.666, P¼ 0.034; Fig. 6a). In a subset of CF patients
(N¼ 114; 57 males and 57 females), Aspergillus-speciﬁc IgE were
also signiﬁcantly higher in IL9 rs2069885-T carriers (general
linear model, P¼ 0.002; Fig. 6b). Notably, in line with the results
obtained on total IgE, the association of IL9 rs2069885-T allele
with higher Aspergillus-speciﬁc IgE levels was observed in females
(linear regression, b¼ 1.417, P¼ 0.002) more than males
(linear regression, b¼ 0.489, P¼ 0.279). We also tested other
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Figure 3 | IL-9 activates mast cells to produce IL-2. C57BL/6 or Cftr/ mice (six per group) infected intranasally with live A. fumigatus conidia were
evaluated at different days after infection (dpi) for (a) deposition of DNA on lung epithelial cells by TUNEL, resulting in bright DNA staining; (b) detection
of c-KitþFceRþ and c-Kitþ IL-9þ lung mast cells (MC) by ﬂow cytometry (numbers refer to percentages of positive cells); (c) toluidine blue, relative MC
number mm 2 and, in the inset, immunohistochemical staining for chymase- and tryptase-positive MC in lung section. Photographs were taken with a
high-resolution microscope (Olympus DP71) equipped with a 40 objective and (in the inset) a  100 objective and with EVOS FL Color Imaging System
with a  60 objective (immunohistochemical staining). (d) Toluidine blue stain and transcription factors expression (PCR with reverse transcription) of
c-Kitþ cells magnetically isolated from lung of uninfected C57BL/6 mice and pulsed with live A. fumigatus conidia. (e) Cytokine production (mean
values±s.d., ELISA on culture supernatants) by puriﬁed lung c-Kitþ cells, pulsed with A. fumigatus and stimulated with IgE, IL-9 and IL-33; (f) detection of
c-Kitþ IL-2þ , CD90.2þ IL-2þ and CD4þ IL-2þ lung cells by ﬂow cytometry (numbers refer to percentages of positive cells). *Po0.05, **Po0.01,
***Po0.001, ****Po0.0001, conidia-pulsed versus unpulsed c-Kitþ cells, stimulated versus unstimulated c-Kitþ cells and Cftr/ versus C57BL/6
c-Kitþ cells (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Mcpt1, mast cell
protease 1; Mcpt6, tryptase beta 2; Rorc, retinoic acid receptor–related orphan receptor C; Rora, RAR-related orphan receptor alpha; Tbet, T box expressed in
T cells; Tph1, tryptophan hydroxylase 1.
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Figure 4 | IL-9 activates mast cells to produce IL-2. MC-deﬁcient C57BL6-KitW/W-v mice (six per group) were infected intranasally with live A. fumigatus
conidia, engrafted intravenously with wild-type bone marrow-cultured mast cells (BMMC) or treated intraperitoneally with IL-2 for a week and assessed for
(a) c-KitþFceRþ lung mast cells (MC) and CD90.2þCD25þ lung ILC2 by ﬂow cytometry (numbers refer to percentages of positive cells) with relative
cell number and (b) IgE and cytokine production. (c) Lung histology (periodic acid–Schiff and Masson’s trichrome staining, in the insets); (d) cytokine
production and (e) Th9-cell speciﬁc transcripts expression in Cftr/ mice infected as above and treated with imatinib intraperitoneally for a week.
Photographs were taken with a high-resolution microscope (Olympus DP71) equipped with a  20 objective, scale bars, 200mm and a 40 objective
(insets of c, scale bars, 100 mm). Results are mean values±s.d., ELISA on lung homogenates for cytokines and PCR with reverse transcription on lung
CD4þTcells. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, MC-deﬁcient C57BL6-KitW/W-v versus C57BL/6 mice or imatinib-treated versus untreated
(none) mice (data represent pooled results or representative images from three experiments, Two-way ANOVA, Bonferroni post test). Irf4¼ interferon
regulatory factor 4; Pu.1¼ purine-rich box 1.
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IL9 tagSNPs (rs2069882, rs31564, rs1859430, rs1799962;
Supplementary Tables 2 and 3), encompassing the whole IL9
gene region, but none associated with IgE levels. Linkage
disequilibrium (LD) analyses of the ﬁve SNPs in IL9 failed to
reveal the presence of signiﬁcant LD blocks (Supplementary
Fig. 7). Haplotype analysis yielded no signiﬁcant result
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Figure 5 | Epithelial and myeloid CFTR deﬁciency contribute to the inﬂammatory phenotype. C57BL/6, Cftr/ and chimeric C57BL/6 and Cftr/
mice (10 per group) received 10 106 viable bone marrow cells 4 weeks before the intranasal infection with A. fumigatus. Chimeric mice were evaluated 7
days after the infection for (a) lung histology (periodic acid–Schiff and, in the insets, Masson’s trichrome and TUNEL staining); (b) cytokines and IgE levels
(mean values±s.d., ELISA on lung homogenates); (c) detection of c-KitþFceRþ mast cells, CD90.2þCD25þ and CD90.2þST2þ type 2 ILCs by ﬂow
cytometry (numbers refer to percentages of positive cells in the lung). Photographs were taken with a high-resolution microscope (Olympus DP71)
equipped with a  20 objective; scale bars, 200mm and a 40 objective (insets of panel a, scale bars, 100mm). *Po0.05, **Po0.01, ***Po0.001,
Cftr/ versus C57BL/6, chimeric C57BL/6 versus C57BL/6, chimeric Cftr/ versus Cftr/ mice, Two-way ANOVA, Bonferroni post test.
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(Supplementary Table 4), although the most common haplotype
C–A–A–C–A (frequency 43.2%) turned out to be associated with
higher IgE levels in males (linear regression, b¼ 0.567,
P¼ 0.022).
We next determined whether the reported sex-speciﬁc
associations could be attributable to a differential expression of
IL9 and its receptor, which is located on the pseudoautosomal
region Xq/Yq, between males and females. A signiﬁcant IL9
rs2069885 by sex interaction was found when analysing the
IL9/IL9R expression ratio (general linear model, P¼ 0.025) where
T allele carriers showed opposite effects according to sex (linear
regression, females, b¼ 0.375, P¼ 0.116; males, b¼  0.426,
P¼ 0.375; Fig. 6c) paralleling the ﬁnding on speciﬁc IgE (Fig. 6a)
and on IL-9 levels in expectorates (Fig. 6d). No signiﬁcant
difference was noticed between males and females when IL9 or
IL9R gene expression levels were analysed independently.
Although these results are to be considered with caution given
the small sample size–despite the sufﬁcient power (b¼ 0.20,
Power¼ 0.8; Supplementary Table 6)—which demands for a
deﬁnitive validation using a larger new cohort of CF patients, the
present ﬁndings conﬁrm the existence of a sex dimorphism at IL9
and IL9R loci, as already reported in several respiratory-related
human phenotypes36,37.
Discussion
We have shown that IL-9 may expand pro-inﬂammatory CD25þ
ILC2/Th9 cell in CF, an activity involving the production of IL-2
by MC. Human MC co-localize near ILC2 in the human lung and
could directly promote ILC2 responses in vitro39. We found here
that, in addition to CD4þ T cells, known to contribute to
CD25þ ILC2 expansion via IL-2 (ref. 8), lung MC may also affect
the expansion of CD25þ ILC2 thought to contribute to chronic
inﬂammation through multiple mechanisms3. Failure to expand
CD25þ ILC2 occurred indeed in MC-deﬁcient mice or mice
treated with imatinib.
MC hyperplasia during chronic allergen challenge is associated
with remodeling of airways40. In a mouse model of ovalbumin-
induced airway inﬂammation, the inﬂux of MC into lung peaks
early after allergen challenge to mature over 14 days into cells
expressing lower level of c-Kit, FceRI and integrins41. MC
hyperplasia was observed in the lung of Cftr /mice along with
the detection of tryptase-positive and chymase-positive MC,
known to be expanded in asthmatic patients42 and in disease
areas of CF lung31. Tryptases and chymases contribute to
inﬂammation and tissue remodeling through the selective
proteolysis of matrix proteins and the activation of protease-
activated receptors and matrix metalloproteinases29. Consistent
with the ﬁnding that MC from CF patients are not high in FceR1
expressing43, we found that lung MC from these mice poorly
responded to IgE in terms of IL-6 production but released IL-2, in
addition to TGF-b, in response to IL-9.
IL-9 is a pleiotropic cytokine that has multiple effects on
structural as well as numerous hematopoietic cells, which are
central to the pathogenesis of asthma44,45. The important role for
the IL-9-MC axis in the pathology associated with chronic allergic
inﬂammation has been already described46. IL-9 not only
stimulates MC growth and expansion but also stimulates
changes in gene expression that might alter responsiveness to
other stimuli47. In vivo, IL-9 governed allergen-induced MC
numbers in the lung, and anti-IL-9 antibody-treatment protected
from airway remodeling, decreased expression of the proﬁbrotic
mediators TGF-b and improved lung function48. The correlation
between a reduction in MC numbers and decreased airway
remodeling, after IL-9 inhibition, is consistent with reports that
MC-deﬁcient mice demonstrate signiﬁcantly attenuated ﬁbrosis
and inﬂammation after silica49, ozone50, or bleomycin injury51.
We found that not only were IL-9 production and MC
expansion signiﬁcantly increased in CF mice but that the
IL-9-MC axis contributed to the expansion of CD25þ ILC2
leading to Th9 cell activation that further contributed to the
allergic inﬂammatory pathology (Fig. 7). IL-9 promoted IL-2
production by lung MC from Cftr /mice, a ﬁnding that may
explain the increased and persistent expansion of CD25þ ILC2 in
these mice. CD25þ ILC2 were indeed not expanded in condition
of IL-9 ablation or MC-deﬁciency, a ﬁnding suggesting that the
IL-9/MC/IL-2 axis drives the expansion of CD25þ ILC2. In
addition, as IL-2 stimulated lung CD25þ ILC2 to produce IL-9
(ref. 9), this may have a positive feedback effect on ILCs, since
lung ILCs cultured with IL-9 increased the production of type 2
cytokines9 and up-regulated the anti-apoptotic protein BCL-3,
thereby promoting ILC2 survival8. Of great interest, Lin cells
from CF lung also promoted Th9 cell activation in vitro, an
activity that required IL-9R expression on responding CD4þ T
cells. Thus, the pathogenic role of IL-9 in promoting allergic
inﬂammation may go beyond CD25þ ILC2 expansion to include
the activation of Th9 cells. That Th9 cells are a major source of
IL-9 in models of allergic inﬂammation and play an important
role in MC accumulation and activation has been reported52. By
producing IL-9, Th9 cells may in turn serve as a positive loop
amplifying the IL-9/MC/ILC2 axis, promoting a deleterious
vicious circle in which the production of proﬁbrotic TGF-b by
IL-9-stimulated MC plays a plausible important role. The
presence of TGF-b dependent signalling in areas of prominent
ﬁbrosis in CF has been already documented24 along with its
inhibition of chloride channel activities53 and the association of
the TGF-b genetic variants with more severe lung disease54.
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Of note, together with IL-4, is able to promote Th9 cell
development in vitro55, a ﬁnding highlighting the potential role
of TGF-b in reinforcing Th9 activity in vivo. However, TGF-b
production by MC in response to IL-9 may also serve a
regulatory, anti-inﬂammatory role11,56.
In addition to IL-9, IL-33 is also a crucial regulator of MC
functions and both IL-33 and MC have been inﬂuentially
associated to the pathophysiology of allergic diseases and
inﬂammation57. IL-33 is expressed in epithelia from patients
with CF and potentiates neutrophil recruitment58 as well as in
type-2 pneumocytes on allergic lung inﬂammation59. In this
study, IL-33 was increased in CF mice and likely correlated with
the expansion of ST2þ ILC2. At variance with IL-2, IL-33 did not
stimulate MC for IL-9/TGF-b production, a ﬁnding indicating a
minor contribution of the IL-33/MC axis in promoting
inﬂammatory allergy and pathology in response to the fungus.
As a matter of fact, the IL-33/MC/IL-2 axis was found
to suppress, rather than promote, papain-induced allergic
inﬂammation by promoting Treg7.
Airway inﬂammation and recurrent pulmonary infections play
a central role in the progression of CF lung disease. It is still an
open question whether CFTR deﬁciency per se may enhance the
inﬂammatory response to the different environmental cues60. Our
data would suggest that CFTR dysfunction on both epithelial and
myeloid cells may impact on the inﬂammatory circuit leading to
the activation of the inﬂammatory IL-9/Th9 pathway: namely,
among others35, on both epithelial damage eventually leading to
overproduction of IL-33 and on the MC propensity to respond to
IL-9 with IL-2. However, PU.1 translocation into the nucleus has
also been shown to be signiﬁcantly higher in CF monocytes than
in controls61. It seems that defective CFTR impacts on the
mechanisms of communication between innate and adaptive
immune response.
The potential contribution of IL-9 to CF pathogenesis in
humans is unknown. Elevated levels of IL-9 were observed in the
expectorates from CF patients, likely accounting for the
expansion of TGF-b-producing MC in diseased lung areas31. It
is of interest that in human asthmatic lung tissue, MC were the
main IL-9R expressing population46. It seems therefore that the
IL-9/MC/IL-2 axis may have a pathogenic role in CF patients and
that its targeting could lead to a reduction in chronic
inﬂammation and improved lung function of these patients.
Studies have indeed highlighted the importance of Th9 cells in
allergic lung inﬂammation by promoting epithelial alterations,
goblet-cell hyperplasia, mucus production and inﬁltration of MC
and eosinophils46. Considering that the costimulatory signal
OX40 is required for Th9 activation62, it is intriguing that OX40
ligand was critical in driving Th2-allergic responses to A.
fumigatus in peripheral CD4þ T cells isolated from CF patients
with ABPA (ref. 63). It is clear that the inﬂammatory response in
the lung involves different Th cell types whose speciﬁc role in CF
remain unclear. Intriguingly, there are conditions where
promoting IL-9 might be therapeutically beneﬁcial11 and ILC2
and MC could be exploited for pathogen immunity and tissue
repair64. In this regard, the fact that imatinib apparently
exacerbated signs of inﬂammation during infection points to a
some beneﬁcial role c-Kitþ cells may have in the control
of Aspergillus infection. MC indeed exhibited conidiocidal
activity (Supplementary Fig. 6d), a ﬁnding suggesting that MC
could serve as tissue sentinels modulating antifungal immune
responses, as suggested65.
In conclusion, IL-9 and MC may have an important role in
the pathogenesis of lung disease and inﬂammation in CF.
Considering the inherent resistance to steroids of MC in
asthmatic patients66, a better understanding of cellular and
molecular pathways leading to inﬂammation and impaired lung
functions may inspire new treatment avenues in patients with CF.
Our study would suggest that imatinib, known to inhibit lung
ﬁbrosis67, could be therapeutically exploited in CF patients with
an exalted IL-9/Th9 responses. In addition, it is of great interest
that the IL9 rs2069885 polymorphism, linked to high IgE levels,
was associated with females more than males with CF, a ﬁnding
offering an explanation for the, as yet unexplained, ‘gender gap’ in
mortality between females and males in CF68 and fostering
gender medicine in CF.
Methods
General experimental approaches. Mice were randomized and assigned to group
allocation at the time of purchase to minimize any potential bias. No blinding was
applied on harvesting cells after the treatments.
Mice. C57BL/6 (wild-type, WT), Rag1 / and MC-deﬁcient C57BL/6-KitW/W-v
mice, 6–8 week old, of both sexes, were purchased from Charles River (Calco,
Italy). Genetically engineered homozygous Cftr / mice69 were bred at the
CF core animal facility at San Raffaele Hospital, Milan, Italy. Il9R / and
RagIl9R / mice were from the Ludwing Institute for Cancer Research, Brussells.
Fungal infection allergy and treatments. Anaesthetized (by inhalation of 3%
isoﬂurane (Forane Abbot) in oxygen)) mice were infected by the intranasal
instillation of 2 107 resting conidia/20 ml saline. For allergic broncho-pulmonary
aspergillosis, A. fumigatus culture ﬁltrate extract in incomplete Freund’s adjuvant
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Figure 7 | Proposed model for the role of IL-9 in promoting a mast
cells/ILC2/Th9 ﬁbrotic pathway in CF. IL-9, produced by IL-33-expanded
ILC2, activates MC for IL-2 production leading to the expansion of
CD25þ ILC2 that promote Th9 cell activation. The resulting increased
production of IL-9 further ampliﬁes the inﬂammatory loop by promoting
ILC2 survival and type 2 cytokines production and by activating MC for the
production of ﬁbrotic TGF-b. IL-9 ablation or MC inhibition (imatinib) are
potential drugable pathways through which inﬂammation and allergy could
be restrained in CF. EC, epithelial cells. aIL-9, IL-9 neutralizing antibody.
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(Sigma-Aldrich) was given (100 mg) to intact mice intraperitoneally (i.p.),
subcutaneously and then intransally (20mg), twice a week apart. A week after
the last intranasal challenge, mice received 107 Aspergillus resting conidia and
evaluated a week later. Murine monoclonal anti-IL-9 antibody (MM9CI from
BioXcell), or control isotype IgG, were administered i.p. at the dose of 500 mg kg 1
for a week starting the day of the infection. The levels of IL-9 after antibody
treatment were 65±15 versus 295±16 pgmg 1 for C57BL/6 and 103±27 versus
719±14 pgmg 1 for Cftr / mice, treated versus untreated mice. IL-2 at the
dose of 1 mg per mouse was given i.p. for a week. Imatinib mesylate (Glivec, ST1571
Novartis, Basel) were administered i.p. at the dose of 1mg kg 1 for a week starting
the day of the infection.
Mast cell engraftment. Selective engraftment of MC in MC-deﬁcient C57BL/
6-KitW/W-v mice was performed as follow. Brieﬂy, bone marrow cells derived from
6-week-old female C57BL/6 mice were cultured in WEHI-3–conditioned medium
(ATCC number TIB-68), as a source of IL-3, for 4–5 weeks to obtain MC
populations (BMCMC) which purity was higher than 95%. Via the tail vein,
5 106 BMCMC were injected into each mouse, and the recipients were used
for experiments 4 weeks later.
Generation of bone marrow chimeras. Femurs and tibias were removed
aseptically from donor C57BL/6 and Cftr / euthanized mice. Bone marrow was
retrieved by ﬂushing with cold Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% heat-inactivated foetal calf serum and 2mM L-glutamine (Invitrogen).
Cells were washed twice with PBS without calcium and magnesium supplemented
with 1% foetal calf serum. Recipient C57BL/6 and Cftr / mice were irradiated
with 9Gy and reconstituted no later than 6 h after the last irradiation with
10 106 T cells by intravenous injection. Mice were given sulfamethoxazole
(150mgml 1) and trimethoprim (30mgml 1) in drinking water for the ﬁrst 3
weeks of reconstitution. Mice were used no earlier than 4 weeks after transplan-
tation. Before use in experiments, all mice were bled from the retro-orbital plexus,
and the peripheral blood lymphocytes were analysed for the stable donor-type
chimerism by reverse transcription-PCR of Cftr.
In vivo staining analysis. For histology, parafﬁn-embedded tissues were stained
with Periodic acid-Schiff, Masson’s trichrome or Toluidine Blue staining to
investigate inﬂammation, collagen deposition and MC inﬁltration, respectively. For
immunoﬂuorescence, lungs were incubated at 4 C with phycoerythrin-conjugated
(PE) anti-CD25 (Miltenyi Biotec clone 7D4, 1:60), anti-T1-ST2 (BioLegend clone
DIH9, 1:400), anti-IL-9 (Milenyi Biotec clone RM9A4, 1:60) and ﬂuorescein iso-
thiocyanate-conjugated (FITC) anti-mouse CD90.2 (Miltenyi Biotecclone 30-H12,
1:60) and anti-CD4 (BioLegend clone GK1.5, 1:1,000). Nuclei were counterstained
with 4,6-diamidino-2-phenylindole. Immunostaining with appropriate irrelevant
antibodies did not give positive staining of the lung. For immunohistochemistry,
the lung sections were incubated overnight with polyclonal anti-chymase (Bioss,
1:100) or monoclonal anti-tryptase (Abcam clone EPR8476, 1:500) followed by the
secondary biotinylated antibodies. Cells were counterstained with haematoxylin.
Photographs were taken using a high-resolution Olympus DP71 microscope with a
 20 and  40 objective or EVOS FL Color Imaging System with a  60 objective.
For immunoblotting, blots of lung lysates were incubated with polyclonal
antibodies against STAT5 and phospho-STAT5 (both from Cell Signaling, 1:1,000)
and normalized on b-actin (clone AC-15 from Sigma). The ChemiDocTM
XRSþ Imaging system (Bio-Rad) was used to detect chemiluminescence on the
addition of the LiteAblotPlus chemiluminescence substrate (Euroclone S.p.A).
Quantiﬁcation was done by densitometry image analysis using Image Lab 5.1
software (Bio-Rad). The uncut blot is shown in Supplementary Fig. 8.
TUNEL assay of lung sections. Sections of lungs ﬁxed in 4% buffered
paraformaldehyde, pH 7.3, for 36 h and embedded in parafﬁn, were deparafﬁnized,
rehydrated, treated with 0.1M citrate buffer, pH 6.0, washed and blocked in 0.1M
Tris-HCl buffer, pH 7.5, supplemented with 3% bovine serum albumin and 20%
foetal calf serum. The slides were then incubated with ﬂuorescein-coupled dUTP
and terminal deoxynucleotidyltransferase–mediated deoxyuridine triphosphate
nick-end labelling (TUNEL) enzyme (Roche Diagnostics) in the presence of
terminal deoxynucleotidyltransferase. Unspeciﬁc binding was removed by washing
with phosphate-buffered saline for 10min at 70 C. The sections were mounted and
analysed by ﬂuorescence microscopy, using a  40 objective.
Cell isolation and culture. Lungs were ﬁnely minced, digested in 16mgml 1
Collagenase P (Roche) for 30min and meshed through a 70-mm cell strainer. ILCs
were isolated from total lung cells by magnetic depletion of Lineage Positive cells
(Miltenyi Biotec). CD4þ T cells and c-Kitþ cells were puriﬁed from total lung
cells after incubation of CD4 microbeads and with PE-labelled anti-c-Kit followed
by anti-PE MicroBeads respectively (both from Miltenyi Biotec). FcERIa-APC
and c-Kit-PE (Miltenyi Biotec) staining and morphological examination after
toluidine blue staining on the cytospin slides were used ﬁr c-Kitþ cell phenotyping.
For Lin -CD4þ T cell co-culture, 2 106 CD4þ T cells were co-cultured with
1 106 Lin cells with or without 50 ngml 1 recombinant IL-33, 40 ngml 1
recombinant IL-2 and pulsed with A. fumigatus conidia. Three days later, IL-9
levels in culture supernatants were analysed by ELISA and Th9 transcription
factors by real-time PCR. To separate Lin and CD4þ T cell, we used the
Transwell culture system (Costar, 0.4 mm pore size; Corning) with CD4þ T cells in
the lower wells and Lin in the upper wells7. For c-Kitþ cells culture, 5 105 cells
were cultured overnight in RPMI medium and pulsed with A. fumigatus conidia
with or without 10mgml 1 IgE, 100 ngml 1 IL-33 and 100 ngml 1 IL-9.
Flow cytometry. Flow cytometry on enriched Lin cells was performed with a
combination of the following ﬂuorescence-conjugated mAbs (all from Miltenyi
Biotec unless speciﬁed otherwise): APC-conjugated anti-NKp46 (29A1.4.9),
anti-CD90.2 (30-H12), anti-Rorg (t; REA278), anti-FcRIa (MAR-1), anti-CD4
(GK1.5); PE-conjugated anti-NK1.1 (PK136), anti-CD25 (7D4), anti-T1-ST2
(DIH9, from Biolegend), anti-CD117 (3C11), anti-IL-9 (RM9A4) and anti-IL-2
(JES6-5H4). For intracellular staining, phorbol 12-myristate 13-acetate (PMA)/
ionomycin-stimulated cells were added of brefeldin, and then permeabilized with
the CytoFix/CytoPerm kit (BD Biosciences) for intra-cytoplasmic detection of IL-9
and IL-2. Flow cytometry was done at 4 C on cells ﬁrst exposed to Fc receptor
mAb (2.4G2). Cells were analysed with a BD LSRFortessa ﬂow cytometer equipped
with BD FACSDiva 7.0 software.
ELISA and real-time PCR. The levels of cytokines and IgE in lung homogenates,
culture supernatants or expectorates were determined by ELISA kits (R&D
Systems) following manufacturer’s instructions. Real-time PCR with reverse
transcription was performed using CFX96 Touch Real-Time PCR Detection
System and SYBR Green chemistry (Bio-Rad) on total RNA reverse transcribed
with the cDNA Synthesis Kit (Bio-Rad). The PCR primers were as listed in
Supplementary Table 5. Ampliﬁcation efﬁciencies were validated and normalized
against Gapdh. The thermal proﬁle for SYBR Green real-time PCR was at 95 C
for 3min, followed by 40 cycles of denaturation for 30 s at 95 C and an
annealing/extension step of 30 s at 60 C. The messenger RNA-normalized data
were expressed as relative gene messenger RNA in treated versus untreated groups
or cells.
Human study. A cohort of 347 patients of Caucasian origin with a proven
diagnosis of CF (CFTR genotyping, sweat testing and clinical phenotype) was
enroled in a prospective multicenter longitudinal genetic association study, See
Supplementary Table 1 for clinical data including age, gender, lung function
testing, measures of nutrition, microbiological ﬁndings and vital status of the
patients’ cohort.
SNPs selection and genotyping. DNA was isolated from blood with the QIAamp
DNA Mini (Qiagen, Milan, Italy) system and stored at  20 C. IL9 SNPs were
selected based on literature review37 and their ability to tag surrounding variants in
the HapMap-CEU population of the International HapMap project, NCBI build
B36 assembly HapMap phase III (http://www.hapmap.org). Haplotype-based
tagging SNPs were selected by assessing LD blocks from the genes of interest with a
pairwise correlation coefﬁcient r2 of at least 0.80 and a minor allele frequency
higher than 5% in the HapMap-CEU population. Five IL9 SNPs complied with the
selection criteria: rs2069885, rs2069882, rs31564, rs1859430 and rs1799962. The
applied Biosystems 7500 Fast qPCR system (Life Technologies) was used for SNP
genotyping by KASPar assays (KBiosciences, Hertfordshire, UK). Each genotyping
set comprised randomly selected replicates of sequenced samples and negative
controls. Agreement between original and duplicate samples was Z99% for all
SNPs. Laboratory personnel were blind to the sample status.
Statistical analysis. Data are expressed as mean±s.d. Horizontal bars
indicate the means. Statistical signiﬁcance was calculated by two-way ANOVA
(Bonferroni’s post hoc test) for multiple comparisons and by a two tailed Student’s
t-test for single comparison. The distribution of levels tested by Kolmogorov–
Smirnov normality test turned out to be non-signiﬁcant. Values of P not 40.05
were considered signiﬁcant. The data reported are either representative from two
or three experiments (FACS data, histology, immunoﬂuoresce and TUNEL assay)
or pooled otherwise. The in vivo groups consisted of 6 mice per group. Data were
analysed by GraphPad Prism 4.03 programme (GraphPad Software). No statistical
method was used to predetermine sample size. Genetic association testing was
carried out considering additive and dominant models by linear regression
implemented in Plink v1.07 (ref. 70), adjusting for age at sampling. Haplotype-
based association tests were performed by general linear model using Plink v1.07
(ref. 70). LD analysis was performed using Haploview, and deﬁning LD blocks
based on the solid spine of LD algorithm. Analyses were conducted stratifying the
study population according to sex since previous evidence highlighted the existence
of sex dimorphism at IL9 locus36,37. IL9 rs2069885 by sex interaction was tested by
general linear model using SPSS v.21. Two-tail P values are reported. Bonferroni’s
correction for multiple testing was not performed since we are assessing speciﬁc
questions on a candidate gene and we are not searching for associations without a
priori hypotheses. Power calculation (using QUANTO v1.2.4) was performed to
determine whether the sample study had sufﬁcient power to detect a signiﬁcant
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association between IL9 rs2069885 and total IgE levels. Considering sample size
(N¼ 237), allele frequency (13%), dominant genetic model, mean level of IgE and
its standard deviation (131.7±248.2 Uml 1) and a¼ 0.05 two-sided, we could
establish that our sample have sufﬁcient power (b¼ 0.20, Power¼ 0.8) to detect an
association explaining more than 3% of total IgE levels variance (Supplementary
Table 6).
Study approval. All animal experiments were approved by local government
authorities and were in agreement with the Italian Approved Animal Welfare
Authorization 360/2015-PR and Legislative decree 26/2014 obtained from the
Italian Ministry of Health lasting and lasting for ﬁve years (2015–2020). Infections
were performed under anaesthesia and all efforts were made to minimize suffering.
Human studies approval was obtained from institutional review boards the
Bambino Gesu` Children’s Hospital (Rome, Italy), Ospedale Maggiore Policlinico,
University of Milan, (Milan, Italy), Innsbruck Medical University, (Innsbruck,
Austria) and Servizio di Supporto Fibrosi Cistica, (Cerignola, Foggia, Italy).
Written informed consent was obtained from the participants, or, in case of
minors, from parents or guardian.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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